top of page

Holistic
Antibody Design

A powerful AI platform for designing antibody 

candidates for in-demand therapies.   

De Novo antibody therapy platform

At Silica Corpora, we design and optimize therapeutic antibodies targeting priority diseases using our proprietary AI-based platform. Our modular system leverages AI-machine learning and data analytics to work exclusively with amino acid sequences.

AdobeStock_569071421.png

Generate antibodies with new levels of efficiency, precision, and control.

Precision Antibody Design 

Using trained AI models on amino acid sequences with trillions of combinations we can identify and generate quality antibodies from scratch.

Generator

Using amino acid sequences, our "Generator" module delivers in return antibody candidates represented as amino acid sequences of heavy and light antibody chains.

Generator 1_edited.jpg

Discriminator

Our Discriminator module predicts with high accuracy the probability of antibody properties including indexing for develop-ability, thermal stability, solubility, self-aggregation, and immunogenicity and more. 

Discriminator 1_edited_edited.jpg

Optimizer

Our Optimizer module adapts candidates to meet a program-specific target product profile (TPP), yielding mutated amino acid sequences of candidates with predicted characteristics.

Optimiser 1 (1)_edited.jpg

Ep-Mapper

Our Ep-Mapper accurately predicts epitopes on the antigen through both antibody-independent and antibody-dependent prediction for linear as well as conformational epitopes. Notably, this mapping is 3D structure-independent.

Epitope Mapping 1_edited.jpg

Our Modules

Inputs are amino acid sequences for therapeutic targets, and the outputs are amino acid sequences identifying novel antibodies in any kind of antibody format, or antibody mutants with improved biochemical properties.

Collaborations

Our strategic partnerships and collaborations drive innovation and foster synergies, enabling us to achieve remarkable results and expand our impact.

Your DeNovo Therapeutics Partner

As a therapeutic development partner, Silica Corpora extracts value from data used in current and previous projects. Our platform can combine with your accumulated data to accelerate current programs, find new value in old data, and improve the quality of drug candidates. 

A new standard for antibody discovery.

Go De Novo

Our platform makes the drug discovery process extremely accurate, extrapolating and narrowing sequences to find ideal candidates in record time and reducing the number of experimental candidates needed in pre-clinical trials.

Precise

Our system is capable of taking into account all set of parameters needed to create a successful candidate and modify them at the same time. This holistic approach is central to our drug discovery philosophy - the system must be considered in its entirety rather than focusing on a single property.

Synergetic 

Our models are specifically designed to work with fine-tuned project-specific data. This allows our platform to find the right answer in every project using only a very small data set, meaning that large amounts of data are not necessarily required.

Efficient

Our De Novo methods do not disrupt existing in vitro workflows. Our methods can be easily adopted alongside established workflows, with no need for new equipment, expertise, or additional personnel.

Adaptive

Our Team

Silica Corpora was founded in 2022, emerging from a shared vision between Tim Ermak and Jaime Rosselló to transform drug discovery through leading-edge, generative technologies.

 

In 2023, the company added Anna-Catharina Krebs as its Chief Scientific Officer. Anna's extensive expertise in lab science accelerated Silica Corpora's capacity to develop its uniquely powerful platform. Driven by a pressing need, Silica Corpora's leadership is driven to confront and rewrite the narrative of escalating costs and time associated with bringing new prescription drugs to market.

Blue Smoke
Abstract Background_edited.jpg
Our mission is to develop advanced De Novo solutions that result in enhanced quality and more cost-effective antibody therapeutics for diseases with high unmet need.
bottom of page